- Home
- ACIU vs SABA Comparison
ACIU vs SABA Comparison
Compare ACIU & SABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- SABA
- Stock Information
- Founded
- ACIU 2003
- SABA 1988
- Country
- ACIU Switzerland
- SABA United States
- Employees
- ACIU N/A
- SABA N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- SABA
- Sector
- ACIU Health Care
- SABA
- Exchange
- ACIU Nasdaq
- SABA Nasdaq
- Market Cap
- ACIU 294.9M
- SABA 248.2M
- IPO Year
- ACIU 2016
- SABA N/A
- Fundamental
- Price
- ACIU $2.65
- SABA $9.14
- Analyst Decision
- ACIU Strong Buy
- SABA
- Analyst Count
- ACIU 2
- SABA 0
- Target Price
- ACIU $12.00
- SABA N/A
- AVG Volume (30 Days)
- ACIU 147.0K
- SABA 290.0K
- Earning Date
- ACIU 03-13-2025
- SABA 01-01-0001
- Dividend Yield
- ACIU N/A
- SABA 12.91%
- EPS Growth
- ACIU N/A
- SABA N/A
- EPS
- ACIU N/A
- SABA N/A
- Revenue
- ACIU $48,505,404.00
- SABA N/A
- Revenue This Year
- ACIU $86.72
- SABA N/A
- Revenue Next Year
- ACIU $118.28
- SABA N/A
- P/E Ratio
- ACIU N/A
- SABA N/A
- Revenue Growth
- ACIU 4097200.00
- SABA N/A
- 52 Week Low
- ACIU $2.25
- SABA $3.64
- 52 Week High
- ACIU $4.98
- SABA $4.42
- Technical
- Relative Strength Index (RSI)
- ACIU 39.10
- SABA 58.93
- Support Level
- ACIU $2.56
- SABA $8.82
- Resistance Level
- ACIU $2.83
- SABA $9.24
- Average True Range (ATR)
- ACIU 0.16
- SABA 0.18
- MACD
- ACIU -0.00
- SABA 0.00
- Stochastic Oscillator
- ACIU 16.85
- SABA 78.26
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Templeton Global Income Fund is a closed-end fund. It seeks high current income, with a secondary goal of capital appreciation. Under normal market conditions. The Fund invests at least over 80% of its net assets in income-producing securities, including debt securities of the United States and foreign issuers, including emerging markets.